Voyager Therapeutics Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -18.0% | -28.7% | -24.8% | +1,270.1% | +63.9% | -78.1% | +9.3% | +511.2% | -68.0% | -49.5% | |
| – | +211.1% | +52.6% | +47.4% | +4.2% | +84.5% | -9.2% | -32.2% | -91.6% | +1,388.8% | -94.9% | +2,695.9% | |
| – | – | -18.0% | -28.7% | -24.8% | +1,270.1% | -40.2% | -40.0% | +9.3% | +285.8% | -49.3% | -214.9% | |
| – | +211.1% | +52.6% | +47.4% | +4.2% | +84.5% | -9.2% | -32.2% | -17.6% | +51.7% | +38.2% | +5.7% | |
| – | +81.2% | +33.9% | +48.7% | +71.3% | +7.5% | -3.7% | +6.4% | -16.8% | +15.6% | +0.3% | +1.5% | |
| – | +161.6% | +47.7% | +47.7% | +20.4% | +58.1% | -77.6% | +217.3% | -17.4% | -61.0% | +355.8% | -75.5% | |
| – | – | – | – | – | – | – | -368.8% | – | – | -168.3% | – | |
| – | – | +194.0% | -100.0% | – | – | – | – | +359.5% | – | – | – | |
| – | – | – | – | – | – | – | -293.8% | – | – | -148.1% | – | |
| – | – | – | -3,167.3% | – | – | – | – | – | +8,700.0% | -52.8% | -78.3% | |
| – | – | – | – | – | – | – | -279.7% | – | – | -149.1% | – | |
| – | – | – | – | – | – | – | -319.4% | – | – | -143.1% | – |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.